Brixton Biosciences is a clinical-stage life sciences company founded in 2018 that focuses on developing novel therapies for chronic and acute pain. The company operates in the biotechnology and information technology industries, with its headquarters in the United States. In its most recent investment round, Brixton Biosciences successfully secured a substantial $33.00M Series B investment on 14 May 2024. The investors in this round included SV Health Investors, Schooner Capital, Excelestar Ventures, Sparta Group, CHV, and PV Capital Management. This significant investment demonstrates the confidence of a consortium of well-established investors in the promising potential of Brixton Biosciences and its innovative approach to addressing unmet needs in pain management. With its ongoing advancements in therapeutic development, the company is poised to make a meaningful impact in the field of life sciences.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $33.00M | 6 |
|
14 May 2024 |
| Venture Round | Unknown | 2 |
|
01 Jan 2021 |
No recent news or press coverage available for Brixton Biosciences.
We care about your data, and we'd love to use cookies make your experience better.